Priapism Management — Pharmacologic Agents
Ischemic priapism requires urgent treatment. This is the drug reference; use the clinical priapism page for diagnosis and the shunts and decompression page for operative decisions. The AUA/SMSNA recommends intracavernosal phenylephrine with aspiration, with or without irrigation, before surgical escalation.[1]
Phenylephrine
Phenylephrine activates α₁ receptors, contracting cavernosal smooth muscle to promote detumescence. Its relative lack of β activity favors it over mixed sympathomimetics; cardiovascular and neurologic complications remain possible.[2]
Adult intracavernosal regimen
| Source | Regimen | Important distinction |
|---|---|---|
| AUA/SMSNA 2022, Appendix A | 100–500 micrograms in 1 mL normal saline, at intervals at least 5 minutes apart, for up to approximately 1 hour | Prefer pharmacy-prepared syringes. Stop injections for blood-pressure changes; persistent ischemia requires escalation, sometimes sooner with prolonged presentation.[1] |
| EAU 2026 | 200 micrograms every 3–5 minutes; maximum 1 mg within 1 hour | Lower doses in children or severe cardiovascular disease; this is a distinct regimen, not an interchangeable universal ceiling.[2] |
Check the amount and final concentration before injection. The AUA preparation contains 100–500 micrograms/mL; concentrated stock vials are not the ready-to-inject preparation. Intracavernosal administration for priapism is off-label. Pediatric dosing needs a specialist protocol rather than extrapolation from an adult syringe.
Monitor blood pressure and pulse during treatment. EAU additionally specifies checks every 15 minutes for 1 hour afterward. Hypertension, reflex bradycardia, tachycardia and serious cerebrovascular events have been reported. EAU advises against sympathomimetics in malignant/poorly controlled hypertension or concurrent monoamine oxidase inhibitors; AUA describes cautious, lower-dose titration with monitoring for MAOI users. Resolve this guideline difference with specialist assessment in the monitored emergency setting.[1][2]
Avoid delays in definitive care
- Aspiration and phenylephrine are complementary. A fully rigid erection after an unsuccessful treatment cycle needs reassessment and prompt urologic escalation; 24–48 hours is not a waiting period before shunting.
- A distal shunt, with or without tunneling, is the usual operative next step. Proximal shunting is not a routine mandatory rung. Persistent tumescence after shunting should be assessed with corporal blood gas or Doppler before another intervention.
- Very prolonged ischemia carries a poor erectile-function prognosis. Discuss prosthesis placement in selected untreated prolonged or refractory cases; duration alone is not an automatic implant order.[1]
Prolonged erection after an ED injection
An erection lasting 4 hours or more requires immediate medical assessment. An earlier, persistent post-injection erection may also need treatment. AUA distinguishes these shorter iatrogenic erections from established ischemic priapism and recommends intracavernosal phenylephrine when intervention is needed. Oral pseudoephedrine or terbutaline should not delay effective treatment; evidence for oral rescue is inconsistent. Avoid ice/cold exposure in sickle cell disease.[3]
The prescribing injection service should provide a clear rescue/contact plan during ICI training. Home phenylephrine is reserved for selected patients with recurrent ischemic priapism who have specific training and an individualized plan. It aborts episodes; it does not prevent them.[3]
Recurrent ischemic (“stuttering”) priapism
There is no established best preventive medication or evidence-based first/second-line drug hierarchy. Balance episode burden, underlying disease, sexual function, fertility and adverse effects with the patient. Hormonal suppression can impair fertility and sexual function; avoid it before sexual maturation.[2][3]
PDE5 inhibitors and the major randomized evidence
Daily sildenafil or tadalafil has been used off-label for prevention, paradoxically aiming to normalize dysregulated erection signaling. Start during a flaccid interval, not as treatment for an acute erection.[2]
| Evidence | What it establishes |
|---|---|
| Burnett 2014: 13 patients with sickle cell disease | Sildenafil 50 mg daily for 8 weeks did not improve the primary outcome versus placebo in the blinded phase. Improvement in 5/8 during open treatment cannot establish comparative efficacy.[4] |
| Cochrane 2020: 3 trials, 102 participants | Evidence for preventing sickle-cell-associated episodes was low or very low certainty. Sildenafil may have little or no effect; etilefrine, ephedrine and stilboestrol remained uncertain. The review predates PIN.[5] |
| PIN, Idris 2025: 64 men with sickle cell anemia | Hydroxyurea plus tadalafil versus hydroxyurea plus placebo: no significant difference in episode rates (reported IRR 0.8, 95% CI 0.3–1.9). This phase 2 feasibility trial had a median 10-month follow-up and was not proof of equivalence.[6] |
PIN's reductions from pretreatment episode rates in both groups are not a randomized estimate of hydroxyurea's effect: there was no group without hydroxyurea. The trial does not establish that adding tadalafil prevents recurrence. See PDE5 inhibitors for contraindications and interactions.[6]
Ketoconazole with glucocorticoid replacement
This is off-label specialist treatment, supported by small uncontrolled series. Hoeh and Levine reported on-treatment resolution in 16/17 patients; the absence of a comparison group prevents ranking it above other options. Their historical regimen is not a validated general prescribing protocol.[7]
Oral ketoconazole has boxed warnings for serious or fatal liver injury and QT-related drug interactions. It is contraindicated in acute or chronic liver disease. Check baseline liver tests and medication interactions; the US label calls for weekly ALT throughout treatment, with interruption if ALT exceeds normal or rises more than 30% from baseline, or liver-injury symptoms develop. Cortisol suppression can cause adrenal insufficiency; glucocorticoid co-treatment does not remove all risk. Suppressing testosterone also requires fertility and sexual-function counseling.[8]
Other preventive approaches
Etilefrine/ephedrine, pseudoephedrine, baclofen, dutasteride and androgen-suppressing agents have limited evidence. They should not appear as a fixed sequence with guaranteed efficacy or routine dose recipes. The Cochrane review found the etilefrine/ephedrine comparison particularly uncertain. Drug selection and monitoring remain individualized; hormonal treatment may be unacceptable when fertility is a priority.[3][5]
Sickle cell disease
Coordinate with hematology, but do not postpone corporal treatment for exchange transfusion. Exchange is not the primary emergency treatment. Longer-term hydroxyurea or transfusion decisions should address the patient's overall sickle cell disease; transfusion targets and peri-anesthetic transfusion are individualized rather than automatic orders for every priapism episode.[3]
Historical alternatives: methylene blue and mixed sympathomimetics
A 2001 methylene-blue series included 12 patients: 10 with injection-induced erections resolved, while the other two did not. This small, selected series does not establish safety or superiority to phenylephrine, and it did not test a standard “after phenylephrine failure” pathway. EAU discusses it among historical alternatives; it should not delay established emergency treatment. For its separate hemolysis and serotonergic interaction risks, see methylene blue.[2][9]
References
1. AUA/SMSNA. The Diagnosis and Management of Priapism (2022): acute ischemic recommendations and Appendices A–B. Official guideline.
2. EAU. Sexual and Reproductive Health Guidelines (2026), Priapism. Current chapter.
3. Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline. J Urol. 2022;208:43–52. doi:10.1097/JU.0000000000002767.
4. Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127:664–668. doi:10.1016/j.amjmed.2014.03.019.
5. Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2020;4:CD004198. doi:10.1002/14651858.CD004198.pub4.
6. Idris IM, Yusuf AA, Ismail II, et al. A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil. Blood. 2025;145:3101–3112. doi:10.1182/blood.2024027898.
7. Hoeh MP, Levine LA. Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes. J Sex Med. 2014;11:197–204. doi:10.1111/jsm.12359.
8. Ketoconazole tablets. US prescribing information: boxed warning, contraindications, hepatotoxicity, adrenal insufficiency and interactions. DailyMed.
9. Martínez Portillo F, Hoang-Boehm J, Weiss J, Alken P, Jünemann K. Methylene blue as a successful treatment alternative for pharmacologically induced priapism. Eur Urol. 2001;39:20–23. doi:10.1159/000052407.